<div id="readability-page-1"><div> (RTTNews) - Longeveron Inc. (LGVN) on Friday announced it held a constructive Type C meeting with the U.S. FDA regarding its ongoing Phase 2b ELPIS II trial of laromestrocel (Lomecel-B) in hypoplastic left heart syndrome (HLHS). The FDA acknowledged HLHS is a rare disease with high unmet need but advised that the trial's primary endpoint, right ventricular ejection fraction (RVEF), is not sufficient to demonstrate efficacy. The company noted that while it agreed with the FDA's concerns, changes to the primary endpoint cannot be made mid-trial due to NIH-mandated interim analysis. As a result, the FDA no longer considers ELPIS II pivotal, but confirmed willingness to revisit the program once results are available. Longeveron intends to submit a Sponsor Statistical Analysis Plan (SAP) with a composite primary endpoint and secondary endpoints for the FDA's review and approval. Longeveron remains optimistic that the ELPIS II results together with other available evidence will be sufficient to support a Biologics License Application (BLA) following the readout. Topline results from the 40-patient, multicentre study are anticipated in August 2026. The trial is capturing objective measures such as mortality, transplant-free survival, and major adverse cardiac events to support efficacy assessment. Laromestrocel has received Orphan Drug, Fast Track, and Rare Pediatric Disease designations for HLHS, making Longeveron eligible for a Priority Review Voucher if approved. HLHS is a congenital defect where the left ventricle is severely underdeveloped or absent, requiring complex staged surgeries. Despite surgical advances, early mortality remains high, underscoring the need for new therapies. The company has scheduled its Q1 2026earnings callon May 13, 2026. LGVN has traded between $0.47 and $1.80 over the past year. The stock closed Friday's trading (May 8, 2026) at $0.84, down 0.77%. During overnight trading, the stock is at $0.77, down 7.99%. The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc. </div></div>

LGVN

SBIO

LABU

IBBQ

Longeveron Inc. (LGVN) held a constructive meeting with the FDA regarding its Phase 2b ELPIS II trial for laromestrocel in hypoplastic left heart syndrome (HLHS). The FDA expressed concerns about the trial's primary endpoint, right ventricular ejection fraction (RVEF), and no longer considers ELPIS II pivotal. Longeveron plans to submit a revised statistical analysis plan and remains optimistic about supporting a Biologics License Application (BLA) after the trial results, expected in August 2026. The stock closed at $0.84, down 0.77%.

nasdaq

Longeveron

First Trust NYSE Arca Biotech Index Fd

ALPS Medical Breakthrough

VanEck Biotech ETF

iShares Biotechnology ETF

Proshares Ultra Nasdaq Biotech

Invesco Biotechnology & Genome ETF

Direxion S&P Biotech Bull 3X

SPDR S&P Biotech

Invesco Nasdaq Biotechnology ETF

Nasdaq

Longeveron Holds Constructive FDA Meeting; ELPIS II Topline Data Expected August 2026